About ReCode Therapeutics
ReCode Therapeutics is a company based in Menlo Park (United States) founded in 2015 by Daniel J Siegwart and Philip Thomas. ReCode Therapeutics has raised $371 million across 8 funding rounds from investors including Amgen, Pfizer and Orbimed. ReCode Therapeutics offers products and services including SORT LNP Platform and Therapeutics Pipeline. ReCode Therapeutics operates in a competitive market with competitors including aTyr Pharma, InterMune, GEn1E, Pulmatrix and Verona Pharma, among others.
- Headquarter Menlo Park, United States
- Founders Daniel J Siegwart, Philip Thomas
- Stage Minicorn
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Recode Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$371 M (USD)
in 8 rounds
-
Latest Funding Round
Not available
-
Investors
Amgen
& 18 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ReCode Therapeutics
ReCode Therapeutics offers a comprehensive portfolio of products and services, including SORT LNP Platform and Therapeutics Pipeline.
Enables targeted delivery of genetic medicines to specific organs
Develops mRNA and gene correction therapies for rare diseases
People of ReCode Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of ReCode Therapeutics
ReCode Therapeutics has successfully raised a total of $371M across 8 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ReCode Therapeutics
ReCode Therapeutics has secured backing from 19 investors, including venture fund and institutional investors. Prominent investors backing the company include Amgen, Pfizer and Orbimed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on healthcare startups
|
Locked | Locked | Locked | |
|
A venture capital firm focused on biotechnology innovations.
|
Locked | Locked | Locked | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked |
Investor details for ReCode Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ReCode Therapeutics
Investment portfolio details for ReCode Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ReCode Therapeutics
Detailed financials for ReCode Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Recode Therapeutics Comparisons
Peer comparison for ReCode Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ReCode Therapeutics
ReCode Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as aTyr Pharma, InterMune, GEn1E, Pulmatrix and Verona Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Protein biologics are developed for treating rare diseases.
|
|
| Locked | Locked | Locked |
Therapies in pulmonology and orphan fibrotic diseases.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of inflammatory and rare diseases
|
|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of respiratory diseases
|
|
| Locked | Locked | Locked |
Respiratory disease drugs for asthma and COPD are developed.
|
Detailed competitors of ReCode Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Recode Therapeutics
Complete news archive for ReCode Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ReCode Therapeutics
ReCode Therapeutics was founded in 2015 and raised its 1st funding round 4 years after it was founded.
ReCode Therapeutics is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
Shehnaaz Suliman is the current CEO of ReCode Therapeutics.
ReCode Therapeutics is a funded company, having raised a total of $371M across 8 funding rounds to date.
ReCode Therapeutics was founded in 2015 and is based in Menlo Park, United States. Precision medicines targeting lung-related diseases are developed, with a focus on the biotech sector. The pipeline features programs for primary ciliary dyskinesia and nonsense mutations in cystic fibrosis. A proprietary non-viral lipid nanoparticle platform is employed to deliver nucleic acid and protein payloads, enabling organ-specific targeting through systemic and local administration routes.
ReCode Therapeutics's top competitors include aTyr Pharma, Pulmatrix and GEn1E.
ReCode Therapeutics offers SORT LNP Platform and Therapeutics Pipeline.
ReCode Therapeutics has 19 investors. Key investors include Amgen, Pfizer, Orbimed, Cystic Fibrosis Foundation, and Tekla Capital Management.
The valuation of ReCode Therapeutics is $372M as of Oct 2021.